| Variable . | 8/8‡ Matched N (%) . | 7/8 HVG MM N (%) . | 7/8 GVH MM N (%) . | 7/8 Both Directions N (%) . | P value . |
|---|---|---|---|---|---|
| Number of patients | 1063 | 112 | 119 | 1393 | |
| Number of centers | 124 | 63 | 60 | 147 | |
| Recipient age, median (range), y | 38 (<1-70) | 34 (4-64) | 31 (<1-65) | 33 (<1-69) | <.0001 |
| Age at transplant, y | <.0001 | ||||
| 0-9 | 76 (7) | 8 (7) | 17 (14) | 141 (10) | |
| 10-19 | 105 (10) | 18 (16) | 16 (13) | 199 (14) | |
| 20-29 | 180 (17) | 16 (14) | 23 (19) | 250 (18) | |
| 30-39 | 209 (20) | 35 (31) | 22 (18) | 284 (20) | |
| 40-49 | 272 (26) | 19 (17) | 21 (18) | 317 (23) | |
| 50 and older | 221 (21) | 16 (14) | 20 (17) | 202 (15) | |
| Recipient race | <.0001 | ||||
| Caucasian | 955 (90) | 90 (80) | 106 (89) | 1121 (80) | |
| African American | 33 (3) | 11 (10) | 5 (4) | 92 (7) | |
| Asian/Pacific Islander | 22 (2) | 5 (4) | 3 (3) | 27 (2) | |
| Hispanic | 41 (4) | 6 (5) | 5 (4) | 133 (10) | |
| Native American | 3 (<1) | 0 | 0 | 6 (<1) | |
| Other | 9 (1) | 0 | 0 | 14 (1) | |
| Male sex | 609 (57) | 61 (54) | 58 (49) | 771 (55) | .31 |
| Karnofsky prior to transplant ≥90 | 717 (73) | 74 (72) | 74 (66) | 934 (71) | .42 |
| Disease at transplant | .003 | ||||
| AML | 399 (38) | 44 (39) | 43 (36) | 503 (36) | |
| ALL | 225 (21) | 24 (21) | 34 (29) | 378 (27) | |
| CML | 270 (25) | 32 (29) | 25 (21) | 362 (26) | |
| MDS | 169 (16) | 12 (11) | 17 (14) | 150 (11) | |
| Disease status at transplant | .96 | ||||
| Early | 762 (72) | 79 (71) | 83 (70) | 978 (70) | |
| Intermediate | 57 (5) | 8 (7) | 7 (6) | 86 (6) | |
| Advanced | 244 (23) | 25 (22) | 29 (24) | 329 (24) | |
| Graft type | .003 | ||||
| Bone marrow | 648 (61) | 76 (68) | 84 (71) | 942 (68) | |
| Peripheral blood stem cell | 415 (39) | 36 (32) | 35 (29) | 451 (32) | |
| In vivo T-cell depletion | .01 | ||||
| No | 850 (80) | 75 (67) | 92 (77) | 1069 (77) | |
| Yes | 213 (20) | 37 (33) | 27 (23) | 324 (23) | |
| GVHD prophylaxis | .001 | ||||
| Tacrolimus ± other | 558 (52) | 54 (48) | 51 (43) | 624 (45) | |
| Cyclosporine ± other | 505 (48) | 58 (52) | 68 (57) | 769 (55) | |
| Donor/recipient sex match | .004 | ||||
| Male/male | 436 (41) | 34 (30) | 40 (34) | 482 (35) | |
| Male/female | 269 (25) | 24 (21) | 35 (29) | 335 (24) | |
| Female/male | 173 (16) | 27 (24) | 18 (15) | 289 (21) | |
| Female/female | 185 (17) | 27 (24) | 26 (22) | 287 (21) | |
| Number of patients | 1063 | 112 | 119 | 1393 | |
| Donor/recipient CMV match | .02 | ||||
| Negative/negative | 354 (33) | 38 (34) | 42 (35) | 426 (31) | |
| Negative/positive | 334 (31) | 32 (29) | 37 (31) | 387 (28) | |
| Positive/negative | 136 (13) | 17 (15) | 23 (19) | 214 (15) | |
| Positive/positive | 190 (18) | 21 (19) | 15 (13) | 319 (23) | |
| Unknown | 49 (5) | 4 (4) | 2 (2) | 47 (3) | |
| Interval from diagnosis to transplant | 9 (<1-296) | 9 (<1-248) | 9 (<1-75) | 11 (<1-309) | .002 |
| HLA matching: HLA-A, HLA-B, HLA-C, and HLA-DRB1 | NA | ||||
| 8/8 matched | 1063 (100) | 0 | 0 | 0 | |
| HLA-A 1 mismatch (MM) | 0 | 34 (30) | 47 (39) | 420 (30) | |
| HLA-B 1 MM | 0 | 7 (6) | 9 (8) | 225 (16) | |
| HLA-C 1 MM | 0 | 57 (51) | 58 (49) | 617 (44) | |
| HLA-DRB1 1 MM | 0 | 14 (13) | 5 (4) | 131 (9) | |
| Donor age | <.0001 | ||||
| Donor age, median (range) | 34 (18-58) | 36 (20-56) | 38 (19-57) | 36 (19-61) | <.0001 |
| 18-29 | 352 (33) | 31 (28) | 22 (18) | 343 (25) | |
| 30-39 | 418 (39) | 37 (33) | 49 (41) | 520 (37) | |
| 40-49 | 235 (22) | 38 (34) | 37 (31) | 398 (29) | |
| 50 and older | 58 (5) | 6 (5) | 11 (9) | 132 (9) | |
| Donor race | <.0001 | ||||
| Caucasian | 925 (87) | 82 (73) | 98 (82) | 1063 (76) | |
| African American | 20 (2) | 7 (6) | 7 (6) | 90 (6) | |
| Asian/Pacific Islander | 22 (2) | 5 (4) | 5 (4) | 32 (2) | |
| Hispanic | 39 (4) | 7 (6) | 1 (1) | 125 (9) | |
| Native American | 7 (1) | 1 (1) | 0 | 16 (1) | |
| Other | 50 (5) | 10 (9) | 8 (7) | 67 (5) | |
| Year of transplant | .001 | ||||
| 1988-1995 | 137 (13) | 18 (16) | 18 (15) | 213 (15) | |
| 1996-2000 | 253 (24) | 26 (23) | 37 (31) | 376 (27) | |
| 2001-2005 | 356 (33) | 44 (39) | 39 (33) | 506 (36) | |
| 2006-2009 | 317 (30) | 24 (21) | 25 (21) | 298 (21) | |
| Median follow-up of survivors, mo (range) | 83 (3-244) | 60 (19-205) | 69 (12-157) | 72 (3-229) | .46§ |
| Variable . | 8/8‡ Matched N (%) . | 7/8 HVG MM N (%) . | 7/8 GVH MM N (%) . | 7/8 Both Directions N (%) . | P value . |
|---|---|---|---|---|---|
| Number of patients | 1063 | 112 | 119 | 1393 | |
| Number of centers | 124 | 63 | 60 | 147 | |
| Recipient age, median (range), y | 38 (<1-70) | 34 (4-64) | 31 (<1-65) | 33 (<1-69) | <.0001 |
| Age at transplant, y | <.0001 | ||||
| 0-9 | 76 (7) | 8 (7) | 17 (14) | 141 (10) | |
| 10-19 | 105 (10) | 18 (16) | 16 (13) | 199 (14) | |
| 20-29 | 180 (17) | 16 (14) | 23 (19) | 250 (18) | |
| 30-39 | 209 (20) | 35 (31) | 22 (18) | 284 (20) | |
| 40-49 | 272 (26) | 19 (17) | 21 (18) | 317 (23) | |
| 50 and older | 221 (21) | 16 (14) | 20 (17) | 202 (15) | |
| Recipient race | <.0001 | ||||
| Caucasian | 955 (90) | 90 (80) | 106 (89) | 1121 (80) | |
| African American | 33 (3) | 11 (10) | 5 (4) | 92 (7) | |
| Asian/Pacific Islander | 22 (2) | 5 (4) | 3 (3) | 27 (2) | |
| Hispanic | 41 (4) | 6 (5) | 5 (4) | 133 (10) | |
| Native American | 3 (<1) | 0 | 0 | 6 (<1) | |
| Other | 9 (1) | 0 | 0 | 14 (1) | |
| Male sex | 609 (57) | 61 (54) | 58 (49) | 771 (55) | .31 |
| Karnofsky prior to transplant ≥90 | 717 (73) | 74 (72) | 74 (66) | 934 (71) | .42 |
| Disease at transplant | .003 | ||||
| AML | 399 (38) | 44 (39) | 43 (36) | 503 (36) | |
| ALL | 225 (21) | 24 (21) | 34 (29) | 378 (27) | |
| CML | 270 (25) | 32 (29) | 25 (21) | 362 (26) | |
| MDS | 169 (16) | 12 (11) | 17 (14) | 150 (11) | |
| Disease status at transplant | .96 | ||||
| Early | 762 (72) | 79 (71) | 83 (70) | 978 (70) | |
| Intermediate | 57 (5) | 8 (7) | 7 (6) | 86 (6) | |
| Advanced | 244 (23) | 25 (22) | 29 (24) | 329 (24) | |
| Graft type | .003 | ||||
| Bone marrow | 648 (61) | 76 (68) | 84 (71) | 942 (68) | |
| Peripheral blood stem cell | 415 (39) | 36 (32) | 35 (29) | 451 (32) | |
| In vivo T-cell depletion | .01 | ||||
| No | 850 (80) | 75 (67) | 92 (77) | 1069 (77) | |
| Yes | 213 (20) | 37 (33) | 27 (23) | 324 (23) | |
| GVHD prophylaxis | .001 | ||||
| Tacrolimus ± other | 558 (52) | 54 (48) | 51 (43) | 624 (45) | |
| Cyclosporine ± other | 505 (48) | 58 (52) | 68 (57) | 769 (55) | |
| Donor/recipient sex match | .004 | ||||
| Male/male | 436 (41) | 34 (30) | 40 (34) | 482 (35) | |
| Male/female | 269 (25) | 24 (21) | 35 (29) | 335 (24) | |
| Female/male | 173 (16) | 27 (24) | 18 (15) | 289 (21) | |
| Female/female | 185 (17) | 27 (24) | 26 (22) | 287 (21) | |
| Number of patients | 1063 | 112 | 119 | 1393 | |
| Donor/recipient CMV match | .02 | ||||
| Negative/negative | 354 (33) | 38 (34) | 42 (35) | 426 (31) | |
| Negative/positive | 334 (31) | 32 (29) | 37 (31) | 387 (28) | |
| Positive/negative | 136 (13) | 17 (15) | 23 (19) | 214 (15) | |
| Positive/positive | 190 (18) | 21 (19) | 15 (13) | 319 (23) | |
| Unknown | 49 (5) | 4 (4) | 2 (2) | 47 (3) | |
| Interval from diagnosis to transplant | 9 (<1-296) | 9 (<1-248) | 9 (<1-75) | 11 (<1-309) | .002 |
| HLA matching: HLA-A, HLA-B, HLA-C, and HLA-DRB1 | NA | ||||
| 8/8 matched | 1063 (100) | 0 | 0 | 0 | |
| HLA-A 1 mismatch (MM) | 0 | 34 (30) | 47 (39) | 420 (30) | |
| HLA-B 1 MM | 0 | 7 (6) | 9 (8) | 225 (16) | |
| HLA-C 1 MM | 0 | 57 (51) | 58 (49) | 617 (44) | |
| HLA-DRB1 1 MM | 0 | 14 (13) | 5 (4) | 131 (9) | |
| Donor age | <.0001 | ||||
| Donor age, median (range) | 34 (18-58) | 36 (20-56) | 38 (19-57) | 36 (19-61) | <.0001 |
| 18-29 | 352 (33) | 31 (28) | 22 (18) | 343 (25) | |
| 30-39 | 418 (39) | 37 (33) | 49 (41) | 520 (37) | |
| 40-49 | 235 (22) | 38 (34) | 37 (31) | 398 (29) | |
| 50 and older | 58 (5) | 6 (5) | 11 (9) | 132 (9) | |
| Donor race | <.0001 | ||||
| Caucasian | 925 (87) | 82 (73) | 98 (82) | 1063 (76) | |
| African American | 20 (2) | 7 (6) | 7 (6) | 90 (6) | |
| Asian/Pacific Islander | 22 (2) | 5 (4) | 5 (4) | 32 (2) | |
| Hispanic | 39 (4) | 7 (6) | 1 (1) | 125 (9) | |
| Native American | 7 (1) | 1 (1) | 0 | 16 (1) | |
| Other | 50 (5) | 10 (9) | 8 (7) | 67 (5) | |
| Year of transplant | .001 | ||||
| 1988-1995 | 137 (13) | 18 (16) | 18 (15) | 213 (15) | |
| 1996-2000 | 253 (24) | 26 (23) | 37 (31) | 376 (27) | |
| 2001-2005 | 356 (33) | 44 (39) | 39 (33) | 506 (36) | |
| 2006-2009 | 317 (30) | 24 (21) | 25 (21) | 298 (21) | |
| Median follow-up of survivors, mo (range) | 83 (3-244) | 60 (19-205) | 69 (12-157) | 72 (3-229) | .46§ |
NA, not available.
Data has been modeled to adjust for oversampling of deceased patients due to a lack of consent for NMDP cases before 2003.
Completeness index follows: Percent with 1-year follow-up: overall: 99%; percent with 3-year follow-up: overall: 95%; percent with 5-year follow-up: overall: 89%.
One or more locus is homozygous in the 8/8 matched category.
This figure is the log-rank P value.